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Abstract
Candida krusei has been documented as an emerging pathogen causing nosocomial outbreaks. The consecutive isolation of C. krusei strains
in three patients admitted to the same hospital department within 2 months lead us to consider the possibility of an outbreak. Additionally,
C. krusei isolates were collected from the room surfaces, whereas another isolate had been recovered from the blood of one patient
2 years before. HinfI DNA restriction endonuclease-based analysis of all C. krusei isolates was performed and restriction proﬁles were com-
pared. Surprisingly, isolates from different patients were unrelated, whereas isolates from biological products of the same patient showed
indistinguishable HinfI restriction patterns and were similar to those obtained from the surrounding environment of the respective patients.
The study approach revealed the endogenous origin of the C. krusei infectious episodes observed and demonstrated that, subsequent to
colonizing a patient, C. krusei can be involved in infectious episodes distant in time. The hypothesis of an outbreak was excluded, although
we believe that the methodology employed in the present study represents a valuable tool for diagnostic and epidemiological surveys.
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Introduction
In the last two decades, invasive fungal infections in hospital-
ized patients have increased signiﬁcantly worldwide. Accord-
ing to data obtained from the USA and Europe, Candida
species represent, respectively, the fourth and sixth most
frequent cause of invasive healthcare-related infections [1,2],
accounting for 8–15% of all episodes of sepsis acquired in
hospital settings [3]. Inherent to these types of infection are
the extremely high morbidity and mortality rates, particularly
among immunocompromised patients [4,5].
Fluconazole is one of the antifungal agents mostly used in
both prophylactic and therapeutic protocols. Fluconazole
prophylaxis has been associated with a decrease in the prev-
alence of Candida species such as Candida tropicalis and
Candida albicans, and to an increase in that of Candida krusei
and Candida glabrata [3]. C. krusei presents intrinsic resistance
to ﬂuconazole and, to some extent, reduced susceptibility to
amphotericin B [6].
Infectious outbreaks in hospitals, especially in intensive
care units, represent a serious health problem and are mainly
due to Candida lusitaniae [7], C. albicans [8], Candida parapsilo-
sis [9], and C. krusei [10,11]. Many factors may account for
their occurrence (e.g. barrier loss, lack of proper infection
control measures by health care workers when managing
patients, resistance to prescribed antifungal drugs, as well as
insufﬁcient drug levels).
Molecular methods represent a powerful tool to clarify
transmission pathways in health care facilities (i.e. to investi-
gate the occurrence of possible outbreaks). Techniques such
as karyotyping, restriction fragment length polymorphism
analysis by pulsed-ﬁeld gel electrophoresis, southern blot
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hybridization, PCR ﬁngerprinting and randomly ampliﬁed
polymorphic DNA ﬁngerprinting have been extensively used
for Candida typing [12–16]. Restriction endonuclease analysis
(REA) has been described in the last decade as a valuable tool
for Candida spp. characterization. REA of the mitochondrial
DNA (mtDNA) was ﬁrst applied in the biotechnology industry
in order to characterize yeast strains used for wine fermenta-
tion [17,18] and, more recently, to discriminate between Can-
dida clinical strains [19–22]. The data obtained demonstrate
the relevance of using molecular genetic methods in many
different areas, including taxonomic, ecological and clinical
surveys.
Recently, we were challenged by a hypothetical outbreak
as a result of C. krusei in the neutropaenia unit of the Hae-
matology Department of Hospital S. Joa˜o, Porto, Portugal.
Within a short period of time, several C. krusei isolates were
cultured from biological products of three patients. In addi-
tion, C. krusei was found in the surrounding environment of
the patients. All isolates were compared using mtDNA REA,
which is a convenient and powerful tool that allows valid
comparisons between isolates of the same yeast species.
Patients and Methods
Patients
Patient A was a 41-year-old male with acute lymphoblastic
leukaemia (T/NK) diagnosed in July 2006. In August 2008,
the patient was initially treated with amoxicillin and cipro-
ﬂoxacin because of undetermined fever. When symptoms
remained unchanged, a myelogram was performed; a ﬁrst
relapse of the haematological disease was diagnosed. He was
admitted to the neutropaenia unit for salvage intensive che-
motherapy with ﬂudarabine, idarubicin and ara-C, followed
by growth factor (G-CSF), administered through a central
venous catheter. Upon the onset of the aplastic period (28
August), he received antimicrobial treatment for 2 weeks
[ciproﬂoxacin, amoxicillin-clavulanic acid, imipenem, acyclovir
and ﬂuconazole (200 mg/day)]. At the time of fungaemia
detection, he displayed the following haematologic parame-
ters: white blood cells 0.03 · 109 cells/L, haemoglobin level
8.5 g/dL and blood platelets 11 · 109 cells/L. As soon as
C. krusei was identiﬁed, the patient was started on caspofun-
gin for 12 days without improvement; the treatment was
then changed to amphotericin B.
This patient had previously developed a fungaemia episode
as a result of C. krusei during chemotherapy in 2006 and a
corresponding isolate had been stored at )70C.
The patient remained in room number 1 from August to
October 2008.
Patient B was a 53-year-old male with non-Hodgkin’s lym-
phoma, who was admitted to room number 2 for 3 weeks in
September 2008. He was administered cyclophosphamide,
doxorubicin, vincristine, and prednisone, followed by G-CSF.
On 12 September 2008, he was started on caspofungin but,
as a result of sustained fever on day 5, treatment was chan-
ged to voriconazole, completing 14 days of antifungal ther-
apy. He never received ﬂuconazole. At that fungaemia
episode, he displayed the following haematologic parameters:
white blood cells 2.41 · 109 cells/L, haemoglobin 9.3 g/dL
and blood platelets 73 · 109 cells/L.
Patient C was a 60-year-old male with acute myeloid leu-
kaemia secondary to myelodisplastic syndrome; he was
admitted to room number 2 for 3 weeks in October 2008,
subsequent to patient B. He received Ara-C, etoposide and
doxorubicin for 5 days, followed by another 5 days of Ara-C;
he was also prescribed amoxicillin, ciproﬂoxacin and allopu-
rinol. In addition, prophylactic treatment included imipenem,
vancomycin, ﬂuconazole and acyclovir from 29 September
to 20 October 2008. On that latest date, he displayed the
following haematologic parameters: white blood cells
0.6 · 109 cells/L, haemoglobin 9.8 g/dL and blood platelets
24 · 109 cells/L.
Patient D served as a typing control; one single C. krusei
isolate was recovered from the patient’s bronchial secretions
in September 2008 upon his admission to the Internal Medi-
cine Department.
Clinical strains
Eighteen C. krusei isolates were collected from different clini-
cal specimens (blood, urine, stools and bronchial secretions)
of the above mentioned patients admitted to the neutropae-
nia unit within a 2-month period. Additionally, a previous
C. krusei isolate (2006) from a blood culture of patient A
was included in the study, as well as a C. krusei isolate
obtained from the control patient D. All isolates were iden-
tiﬁed using the automatic system Vitek2 YBC identiﬁcation
cards (BioMe´rieux, Paris, France), stored at )70C in Brain
Heart infusion (Merck KGaA, Darmstadt, Germany) with
10% glycerol and sub-cultured twice on Sabouraud agar
(Merck KGaA) to ensure purity prior to experimental
assays.
Environmental strains
Several environmental samples were collected from the
patients’ rooms (1 and 2) using Sabouraud agar contact
plates (Merck KGaA); two C. krusei isolates were cultured:
one from the bedside table of patient A (room 1) and
another from the bed of patient C (room 2). The isolates
were characterized and stored as described above for clinical
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samples. Air samples were collected by ﬁltration with a
MAS-100 Eco instrument (Merck Eurolab, Dietlikon, Switzer-
land), containing Sabouraud agar plates (Merck KGaA); no
C. krusei isolates were obtained.
Antifungal susceptibility testing
Voriconazole (Pﬁzer, New York, NY, USA), posaconazole
(Schering-Plough; Kenilworth, NJ, USA), amphotericin B
(Bristol Meyers Squibb, New York, NY, USA), caspofungin
(Merck, Rahway, NJ, USA) and anidulafungin (Pﬁzer) stock
solutions were prepared according to CLSI protocols (M27-
A3) [23] and maintained at )70C until use. Minimal inhibi-
tory concentration (MIC) of each antifungal drug was deter-
mined according to CLSI protocol M27-A3 [23].
Total genomic DNA extraction
Yeast cells were cultured overnight at 30C in 10 mL of
YPD liquid medium, with continuous orbital shaking at
180 r.p.m., and subsequently collection by centrifugation.
Total DNA was extracted using phenol:chloroform:isoamyl
alcohol 25:24:1, precipitated using 100% ice-cold ethanol and
redissolved in 200 lL of TE buffer. The DNA was treated
with 20 lg of RNase (Applichem, Darmstadt, Germany),
incubated at 37C for 30 min to 1 h. For ﬁnal precipitation,
20 lL of 4 M ammonium acetate, pH 4.8 (Sigma-Aldrich,
Munich, Germany) and 600 lL of ice-cold 100% ethanol
(Applichem) were added and samples were incubated over-
night at )20C. The DNA was re-dissolved in TE buffer 1x,
assessed in a biophotometer 6131 (Eppendorf, Hamburg,
Germany) and adjusted to a ﬁnal concentration of 2.0–
2.5 lg/lL. To assay DNA integrity, approximately 3–5 lg
of DNA was run in agarose gel (1%, w/v) (Sigma-Aldrich)
in TBE buffer 1x and stained with ethidium bromide (0.5
mg/mL) (Applichem). DNA samples were stored at )20C
for subsequent use.
REA of mt DNA
For each sample, a reaction mixture was prepared containing
1x HinfI enzyme reaction buffer (Metabion, Planegg, Ger-
many), 1 lg/lL RNase, 0.5 U/lL HinfI restriction enzyme
(Metabion), approximately 25–30 lg of total DNA and
DNAse-RNAse free water up to 20 lL ﬁnal volume; reaction
tubes were incubated overnight at 37C. Restriction was
ended upon HinfI inactivation by incubating for 20 min at
80C. The total reaction mixture was run on a 1% agarose gel
(20 cm · 24 cm) at 120 mV for 3–5 h, stained with ethidium
bromide (0.5 mg/mL) and the DNA visualized under UV light.
Restriction patterns were analyzed using the UVIDOC
12.6 software for Windows (Topac Inc., Cohasset, MA,
USA) and the resulting groups of strains were compared.
Results and Discussion
There have been an increasing numbers of reports describing
non-albicans Candida hospital outbreaks. Given that C. krusei is
not the main pathogen causing nosocomial infections, the
detection of simultaneous episodes at the neutropaenia unit of
our hospital lead us to consider the possibility of an outbreak.
The C. krusei isolates were all susceptible to all the anti-
fungals assayed (ﬂuconazole was not tested because C. krusei
presents intrinsic resistance to this agent). Variations in the
antifungal MICs for different isolates were not signiﬁcant.
The MICs of amphotericin B were from 0.06 to 1 mg/L; for
caspofungin from 0.125 to 1 mg/L; for anidulafungin 0.06 mg/
L; for voriconazole from 0.25 to 2 mg/L; and for posaconaz-
ole from 0.03 to 0.5 mg/L.
The routine biochemical identiﬁcation protocols or anti-
fungal susceptibility proﬁles are usually not sufﬁcient to
either corroborate or exclude an outbreak hypothesis. REA
for Candida species was ﬁrst described by Scherer and Ste-
vens [24] who considered this method to be an extremely
valuable tool for epidemiological studies. Fujita et al.[21]
described HinfI restriction patterns as exhibiting a superior
discriminatory power among distinct Candida isolates com-
pared to patterns obtained with other enzymes such as
EcoRI or MspI. Additionally, Sancak et al.[22] established a
correspondence of almost 100% between the results
obtained with HinfI restriction endonuclease-based analysis
and PCR methodologies. In the present study, a total of 22
C. krusei isolates (20 clinical, two environmental) were ana-
lyzed using REA. A high number of C. krusei isolates was
obtained from different biological products of patient A in
distinct periods of time. All of them showed the same
restriction pattern, including the isolate recovered in 2006
from a blood culture (ABC1) (Fig. 1, lanes ABC1, ABC2 and
ACVCII), indicating that they are the same strain. Most cer-
tainly, this patient harbors a reservoir of C. krusei and was
colonized throughout a long period of time, as described
similarly for Acinetobacter [25] and Pseudomonas [26]. This is
the ﬁrst report, to our knowledge, describing a long-lasting
colonization by C. krusei. These results have implications in
terms of prophylactic measures (i.e. ﬂuconazole is not rec-
ommended in a patient with previous isolation of C. krusei).
Other antifungals, such voriconazole or amphotericin B, are
more likely to be efﬁcient in these cases [27,28].
The C. krusei isolates from each patient yielded distinct HinfI
restriction patterns, suggesting that the isolates were different
strains (Fig. 1, lanes ABC2, BBS, CS), at the same time discarding
the hypothesis of an outbreak in the neutropaenia unit where
the patients were admitted. The C. krusei strain isolated from
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patient D showed a pattern distinct from those isolated from
the remaining patients (Fig. 1, lane DBS), as expected.
The two environmental C. krusei isolates collected from
the surfaces of the rooms where patient A (AE9) (room 1)
and patients B and C (CE) (room 2) had stayed were
different, as depicted in Fig. 1. This excludes the possibility
of different C. krusei strains being transmitted as a result of
patient handling by health care workers. However, both the
environmental and the clinical C. krusei isolates associated
with the same patient displayed an undistinguishable restric-
tion pattern, as shown in Fig. 1 (lanes ACVC11 and AE9 vs. CS
and CE), suggesting a putative environmental reservoir and
the possibility of subsequent transmission from it to other
patients. Our results emphasize the need to enhance preven-
tive infection control measures, both when handling the
patients directly and when cleaning patients¢ facilities, particu-
larly those admitting neutropenic patients. Indeed, a study by
Berrouane et al. [29] described the relatedness among C. kru-
sei clinical isolates obtained from different biological products
from both patients and health care workers.
As described in the present study, we were able to
exclude the hypothesis of an outbreak occurring in the neu-
tropaenia unit throughout the time period considered, sup-
porting the usefulness and suitability of the REA
methodology. Moreover, the present study provided very
useful information concerning C. krusei reservoirs existing in
patients and their surrounding environment.
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